1-(4-methoxyphenyl)-6-(2-pyrrolidin-1-ylethyl)-3-trifluoromethyl-1,4,5,6-tetrahydropyrazolo[3,4-c]pyridin-7-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(4-methoxyphenyl)-6-(2-pyrrolidin-1-ylethyl)-3-trifluoromethyl-1,4,5,6-tetrahydropyrazolo[3,4-c]pyridin-7-one
• 英文别名: 1-(4-Methoxyphenyl)-6-(2-pyrrolidin-1-ylethyl)-3-(trifluoromethyl)-4,5-dihydropyrazolo[3,4-c]pyridin-7-one
• 化学式: C₂₀H₂₃F₃N₄O₂
• 分子量: 408.423
• InChiKey: XNODKAMKPBVOIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  50.6
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
  申请人：——

  公开号：US20040214808A1

  公开（公告）日：2004-10-28

  The present application describes linear chain substituted monocyclic and bicyclic compounds and derivatives thereof of Formula I: P 4 -P-M-M 4 I or pharmaceutically acceptable salt forms thereof, P-M are rings substituted by a linear group. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

  本申请描述了公式I：P4-P-M-M4I的线性链取代的单环和双环化合物及其衍生物，或其药学上可接受的盐形式，其中P-M是由线性基团取代的环。本发明的化合物可用作胰蛋白酶样丝氨酸蛋白酶的抑制剂，特别是因子Xa的抑制剂。
• LINEAR CHAIN SUBSTITUTED MONOCYCLIC AND BICYCLIC DERIVATIVES AS FACTOR XA INHIBITORS
  申请人：Brystol-Myers Squibb Company

  公开号：EP1603909A2

  公开（公告）日：2005-12-14
• EP1603909A4
  申请人：——

  公开号：EP1603909A4

  公开（公告）日：2008-09-03
• US7135469B2
  申请人：——

  公开号：US7135469B2

  公开（公告）日：2006-11-14
• [EN] LINEAR CHAIN SUBSTITUTED MONOCYCLIC AND BICYCLIC DERIVATIVES AS FACTOR XA INHIBITORS<br/>[FR] DERIVES MONOCYCLIQUES ET BICYCLIQUES A CHAINE LINEAIRE SUBSTITUEE UTILISES EN TANT QU'INHIBITEURS DU FACTEUR XA
  申请人：BRYSTOL MYERS SQUIBB COMPANY

  公开号：WO2004083177A2

  公开（公告）日：2004-09-30

  The present application descirbes linear chain subtituted monocyclic and byciclic compounds and derivatives thereof of formula (I): P4-P-M-M4 or pharmaceutically acceptable salts from thereof, P-M are rings substituted by a linear group. Compounds of the present invention are useful as inhibitors of trypsin like serine proteases, specifically factor Xa.